Goldenrod Therapeutics, Inc. raises $6.5 million in a Series Seed round led by Ataxia Ventures and Fannin Partners to fund its 11h program targeting brain inflammation.
Amount Raised
$6.5 Million
Round Type
Seed
HoustonBiotechnologyHealth CareTherapeuticsInvestors
Description
Goldenrod Therapeutics, Inc. has completed an initial closing under its $6.5 million Series Seed preferred stock round. The funding will support manufacturing and studies for its next-generation PDE4 inhibitor, aimed at treating Friedreich’s Ataxia. CEO Dev Chatterjee states this advancement could lead to a best-in-class therapy for neurodegenerative diseases
Quick answer
Goldenrod Therapeutics raised $6.5 Million in a Seed round, dated June 4, 2026. Investors: Ataxia Ventures and Fannin Partners. Goldenrod Therapeutics is based in Houston, Texas, United States.
- How much did Goldenrod Therapeutics raise?
- Goldenrod Therapeutics raised $6.5 Million in a Seed round on June 4, 2026.
- Who invested in Goldenrod Therapeutics?
- Ataxia Ventures and Fannin Partners are named as investors in this round.
- What does Goldenrod Therapeutics do?
- Goldenrod Therapeutics, Inc. is a Fannin-founded precision therapeutics company developing novel brain-penetrant therapies that target neuroinflammation and neuronal signaling pathways implicated in neurodegenerative..
- Where is Goldenrod Therapeutics based and how big is it?
- Goldenrod Therapeutics is based in Houston, Texas, United States.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Goldenrod Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- ME Therapeutics Holdings raised $457K (Post-IPO Equity) on July 17, 2026.
- Sightera Biosciences raised $3.4M (Pre-Seed) on July 17, 2026.
- Georgiamune raised $93M on July 16, 2026.
- Crescent Biopharma raised $8.1M (Post-IPO Equity) on July 15, 2026.
- AdvanCell raised $315M (Series D) on July 15, 2026.
- Draig Therapeutics raised $65M (Series B) on July 14, 2026.
Who to call at Goldenrod Therapeutics, and when
A new round usually means Goldenrod Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Goldenrod Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Goldenrod Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Goldenrod Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Goldenrod Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Goldenrod Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.